Beta Bionics, Inc. Increase (Decrease) in Accounts Payable
Beta Bionics, Inc. (BBNX) reported Increase (Decrease) in Accounts Payable of -$471.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-07-29
- Beta Bionics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $2.86M, a 403.87% increase year-over-year.
- Beta Bionics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$3.33M.
- Beta Bionics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $527.00K.
- Beta Bionics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $1.10M, a 937.74% increase year-over-year.
- Beta Bionics, Inc. increase (decrease) in accounts payable for fiscal 2025 was $2.10M, a 38.48% increase from fiscal 2024.
- Beta Bionics, Inc. increase (decrease) in accounts payable for fiscal 2024 was $1.51M, a 111.59% increase from fiscal 2023.
- Beta Bionics, Inc. increase (decrease) in accounts payable for fiscal 2023 was $716.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$471.00K 10-Q · filed 2026-07-29 | $56.00K derived: sum of 3 quarters · filed 2026-07-29 | $1.16M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | -$3.33M 10-Q · filed 2026-04-21 | -$2.81M derived: sum of 2 quarters · filed 2026-04-21 | -$1.71M derived: sum of 3 quarters · filed 2026-04-21 | -$1.14M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $527.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.63M derived: sum of 2 quarters · filed 2026-02-24 | $2.19M derived: sum of 3 quarters · filed 2026-07-29 | $2.10M 10-K · filed 2026-02-24 |
| 2025-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $1.67M derived: sum of 2 quarters · filed 2026-07-29 | $1.57M 10-Q · filed 2025-10-28 | $1.51M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $568.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $471.00K 10-Q · filed 2026-07-29 | $410.00K derived: sum of 3 quarters · filed 2026-07-29 | $516.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | -$97.00K 10-Q · filed 2026-04-21 | -$158.00K derived: sum of 2 quarters · filed 2026-04-21 | -$52.00K derived: sum of 3 quarters · filed 2026-04-21 | $1.01M derived: sum of 4 quarters · filed 2026-04-21 |
| 2024-12-31 | -$61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $45.00K derived: sum of 2 quarters · filed 2026-02-24 | $1.10M derived: sum of 3 quarters · filed 2026-02-24 | $1.51M 10-K · filed 2026-02-24 |
| 2024-09-30 | $106.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $1.17M derived: sum of 2 quarters · filed 2025-10-28 | $1.58M 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $1.47M 10-Q · filed 2025-07-29 | ||
| 2024-03-31 | $410.00K 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $716.00K 10-K/A · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |